Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
The new Zigly center features and offers comprehensive veterinary services
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
Subscribe To Our Newsletter & Stay Updated
